ZTX models can be established directly from patient samples and accurately predict patient treatment outcomes. A,B Quantification of the relative treatment-induced tumor regression of tumors established from 9 PDX models calculated as the change in tumor size between day 3 and 0 after implantation, in groups treated with Erlotinib 10 mg/L (A) or Paclitaxel 20 mg/L (B), divided by the change in tumor size in the control group. n = 13–19. Gray bars indicate models from patients that were not treated with the indicated drug and red bars indicate models from patients that had progressed following treatment with the indicated drug. *: p < 0.05. C Quantification of the average number of metastasized cells at three days after implantation for each of the 9 validation models. n = 13–19. Green bar indicates a model from a patient with a localized cancer, red bars indicate models from patients with disseminated cancer and grey bars indicate models from patients with unknown lymph node or metastatic status. Black dashed line indicates the cut-off level for prediction of disseminated disease by the ZTX model. D H&E micrographs of tumor sections from the four patients included in this study. E-H Quantification of the relative growth (E), average number of metastasized cells (F), and relative Erlotinib- or Paclitaxel-induced tumor regression (G and H respectively), calculated as in A/B, for the four patients included in this study. Dashed line indicates the cut-off level for predicting disseminated disease. n = 14–20
|
